

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM S-8  
REGISTRATION STATEMENT UNDER THE  
SECURITIES ACT OF 1933

**NextCure, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or  
organization)

**47-5231247**  
(I.R.S. Employer  
Identification No.)

**9000 Virginia Manor Road, Suite 200**  
**Beltsville, Maryland 20705**  
(Address, including zip code, of  
principal executive offices)

**NEXTCURE, INC. 2019 OMNIBUS INCENTIVE PLAN**  
(Full title of the plan)

**Michael Richman**  
Chief Executive Officer  
NextCure, Inc.

**9000 Virginia Manor Road, Suite 200**  
**Beltsville, Maryland 20705**  
**(240) 399-4900**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

**With Copies to:**

**Asher M. Rubin**  
Sidley Austin LLP  
2850 Quarry Lake Dr., Suite 301  
Baltimore, MD 21209  
(312) 853-7000

**Steven P. Cobourn**  
Chief Financial Officer  
NextCure, Inc.  
9000 Virginia Manor Road, Suite 200  
Beltsville, Maryland 20705  
(240) 399-4900

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.

**CALCULATION OF REGISTRATION FEE**

<b>Title of Each Class of Securities to be Registered</b>	<b>Amount to be Registered(1)</b>	<b>Proposed Maximum Offering Price Per Share</b>	<b>Proposed Maximum Aggregate Offering Price</b>	<b>Amount of Registration Fee</b>
Common Stock, \$0.001 par value per share	2,202,722	\$ 8.22	(2) \$ 18,106,374.84 (2)	\$ 1,678.46

- (1) Consists for shares available for issuance under the NextCure, Inc. 2019 Omnibus Incentive Plan (the "2019 Omnibus Plan"). The number of shares of Common Stock, \$0.001 par value per share (the "Common Stock"), available for issuance under the 2019 Omnibus Plan is subject to an automatic annual increase on January 1st of each year, commencing on January 1, 2020 and continuing until the expiration of the 2019 Omnibus Plan, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year (the "2019 Omnibus Plan Evergreen Provision"). Accordingly, the number of shares of Common Stock available for issuance under the 2019 Omnibus Plan was increased by 2,202,722 shares, which is equal to the sum of (i) 4% of the total number of shares of Common Stock outstanding as of December 31, 2019 and (ii) 4% of the total number of shares of Common Stock outstanding as of December 31, 2020. This

Registration Statement registers the 2,202,722 additional shares of Common Stock available for issuance under the 2019 Omnibus Plan as of January 1, 2021 as a result of 2020 and 2021 increases due to the 2019 Omnibus Plan Evergreen Provision. In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the registrant’s common stock that become issuable under the 2019 Omnibus Plan by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.

- (2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and aggregate offering price are based on the average of the high and the low price of the registrant’s common stock as reported on The Nasdaq Global Select Market on October 29, 2021.
- 
-

## EXPLANATORY NOTE

This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by NextCure, Inc., a Delaware corporation (the “Registrant”), relating to 2,202,722 shares of its Common Stock, par value \$0.001 per share (the “Common Stock”), issuable to eligible employees under the NextCure, Inc. 2019 Omnibus Incentive Plan. The Registrant filed with the Securities and Exchange Commission (the “Commission”) on May 13, 2019 a Registration Statement on [Form S-8 \(Registration No. 333-231436\)](#) (the “Prior Registration Statement”). This Registration Statement relates to securities of the same class as those to which the Prior Registration Statement relates and is submitted in accordance with General Instruction E of Form S-8 regarding the Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statement are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

## PART II

### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### **Item 3. Incorporation of Documents by Reference.**

The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:

- (a) the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on [March 4, 2021](#) and as amended on [April 26, 2021](#);
- (b) the Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021, June 30, 2021 and September 30, 2021, filed with the Commission on [May 6, 2021](#), [August 5, 2021](#) and November 4, 2021, respectively;
- (c) the Registrant’s Current Reports on Form 8-K, filed with the Commission on [February 24, 2021](#), [May 6, 2021](#), [June 25, 2021](#), [September 24, 2021](#) and [October 4, 2021](#); and
- (d) [The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A \(File No. 001-38905\), filed with the Commission on May 8, 2019 under Section 12\(b\) of the Securities Exchange Act of 1934, as amended \(the “Exchange Act”\), including any amendments or reports filed for the purpose of updating such description.](#)

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and will be part hereof from the date of filing of such documents; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

---

**Item 8. Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
<u>4.1*</u>	<a href="#">Amended and Restated Certificate of Incorporation of NextCure, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on May 13, 2019)</a>
<u>4.2*</u>	<a href="#">Amended and Restated Bylaws of NextCure, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed with the Commission on May 13, 2019)</a>
<u>4.3*</u>	<a href="#">NextCure, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to the Registrant's Registration Statement on Form S-1 filed with the Commission on April 29, 2019)</a>
<u>5.1**</u>	<a href="#">Opinion of Sidley Austin LLP</a>
<u>23.1**</u>	<a href="#">Consent of Independent Registered Public Accounting Firm</a>
<u>23.2**</u>	<a href="#">Consent of Sidley Austin LLP (included in Exhibit 5.1)</a>
<u>24.1**</u>	<a href="#">Power of Attorney (contained in signature page to this Registration Statement)</a>

\* Previously filed with the Commission and incorporated herein by reference.

\*\* Filed herewith.

---

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Beltsville, in the State of Maryland, on November 4, 2021.

### NEXTCURE, INC.

By: /s/ Steven P. Cobourn

Steven P. Cobourn

Chief Financial Officer

---

## POWER OF ATTORNEY AND SIGNATURES

The undersigned officers and directors of NextCure, Inc., a Delaware corporation (the “Company”), hereby constitute and appoint Michael Richman and Steven P. Cobourn, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said agents and attorneys-in-fact, and each of them, to sign for the undersigned, individually and in each capacity stated below, one or more Registration Statements on Form S-8 of the Company to be filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, and any amendment or amendments to each such Registration Statement, relating to securities of the Company acquired under the NextCure, Inc. 2019 Omnibus Incentive Plan, and hereby ratify and confirm all acts taken by such agents and attorneys-in-fact, or either of them, as herein authorized.

<u>Name</u>	<u>Title</u>	<u>Date</u>
/s/ Michael Richman Michael Richman	President, Chief Executive Officer and Director (Principal Executive Officer)	November 4, 2021
/s/ Steven P. Cobourn Steven P. Cobourn	Chief Financial Officer (Principal Financial and Accounting Officer)	November 4, 2021
/s/ David Kabakoff, Ph.D. David Kabakoff, Ph.D.	Chair of the Board of Directors	November 4, 2021
/s/ John G. Houston, Ph.D. John G. Houston, Ph.D.	Director	November 4, 2021
/s/ Elaine V. Jones, Ph.D. Elaine V. Jones, Ph.D.	Director	November 4, 2021
/s/ Chau Q. Khuong Chau Q. Khuong	Director	November 4, 2021
/s/ Garry A. Nicholson Garry A. Nicholson	Director	November 4, 2021
/s/ Stephen W. Webster Stephen W. Webster	Director	November 4, 2021

November 4, 2021



SIDLEY AUSTIN LLP  
ONE SOUTH DEARBORN STREET  
CHICAGO, IL 60603  
+1 312 853 7000  
+1 312 853 7036 FAX

AMERICA · ASIA PACIFIC · EUROPE

NextCure, Inc.  
9000 Virginia Manor Road  
Suite 200  
Beltsville, MD 20705

Re: 2,202,722 Shares of Common Stock, \$0.001 par value per share

Ladies and Gentlemen:

We refer to the Registration Statement on Form S-8 (the “Registration Statement”) being filed by NextCure, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration of 2,202,722 shares of Common Stock, \$0.001 par value per share (the “Registered Shares”), of the Company which may be issued under the NextCure, Inc. 2019 Omnibus Incentive Plan (the “Plan”).

This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

We have examined the Registration Statement, the Company’s Amended and Restated Certificate of Incorporation, the Company’s Amended and Restated Bylaws, the Plan and the resolutions adopted by the board of directors of the Company relating to the Registration Statement and the Plan and the resolutions adopted by the stockholders of the Company relating to the Plan. We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company.

Based on the foregoing, we are of the opinion that each Registered Share that is newly issued pursuant to the Plan will be validly issued, fully paid and non-assessable when: (i) the Registration Statement, as finally amended, shall have become effective under the Securities Act; (ii) such Registered Share shall have been duly issued and delivered in accordance with the Plan; and (iii) certificates representing such Registered Share shall have been duly executed, countersigned and registered and duly delivered to the person entitled thereto against payment of the agreed consideration therefor (in an amount not less than the par value thereof) or, if any Registered Share is to be issued in uncertificated form, the Company’s books shall reflect the issuance of such Registered Share to the person entitled thereto against payment of the agreed consideration therefor (in an amount not less than the par value thereof), all in accordance with the Plan.

Sidley Austin LLP is a limited liability partnership practicing in affiliation with other Sidley Austin partnerships.

---

# SIDLEY

NextCure, Inc.  
November 4, 2021  
Page 2

This opinion letter is limited to the General Corporation Law of the State of Delaware. We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.

We hereby consent to the filing of this opinion letter as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

Very truly yours,

/s/ Sidley Austin LLP

---

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the NextCure, Inc. 2019 Omnibus Incentive Plan of our report dated March 4, 2021, with respect to the financial statements of NextCure, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2020, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Baltimore, MD  
November 4, 2021

---